Key clinical point: Two Food and Drug Administration-approved protocols for repetitive transcranial magnetic stimulation were safe and effective as adjunct treatments for major depressive disorder.

Major finding: The remission rate was significantly higher for patients treated with either H1-coil and standard pharmacotherapy (odds ratio, 11.3) or 8-coil and standard pharmacotherapy (OR, 7.20), compared with control patients who received standard pharmacotherapy only.

Study details: The data come from randomized, controlled, single-blind trial of 228 adults with major depressive disorder.

Disclosures: The researchers had no financial disclosures. The study was funded by the Sveti Ivan Psychiatric Hospital in Zagreb, Croatia.